Drug Profile
Research programme: interferon lambda therapeutics - Synairgen
Alternative Names: IFN-lambdaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Imperial Innovations
- Developer Synairgen
- Class Interferons
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 19 Mar 2014 Discontinued - Preclinical for Respiratory tract disorders in United Kingdom (unspecified route)
- 12 Sep 2006 Preclinical trials in Respiratory tract disorders in United Kingdom (unspecified route)